Hot Natural Products & Bioactive Compounds
BioCrick offers high-purity natural products and bioactive compounds for scientific research. Our natural product collection includes compounds derived from plants, microorganisms and other biological sources and is widely used in pharmacological, biochemical and drug discovery research.
Natural products remain an important source of bioactive molecules and drug leads. BioCrick provides researchers with high-quality natural product compounds together with catalog numbers, product information and biological activity data.
Hot Products from BioCrick
Showing 121 - 128 of 9359 hot products
| Catalog No. | Product Name |
|---|---|
| BCC1246 | Scrambled 10Panx |
|
Scrambled version of <sup>10</sup>Panx, a Panx-1 mimetic inhibitory peptide that blocks pannexin-1 gap junctions, inhibits P2X<sub>7</sub>-mediated dye uptake, ATP-mediated IL-1<span class='symbol'>β</span> release and caspase-1 activation without altering membrane current in macrophages <em>in vitro</em>. <sup>10</sup>Panx also blocks activation of NMDA receptor secondary currents (I<sub>2nd</sub>) by > 70%.
|
|
| BCC1251 | Ivermectin |
|
Positive allosteric modulator of the <span class='symbol'>α</span>7 neuronal nicotinic acetylcholine receptor and the purinergic P2X<sub>4</sub> receptor. Antihelmintic. Also modulates glutamate- and GABA-activated chloride channels. Potentiates glycine-gated currents at low concentrations (30 nM).
|
|
| BCC1254 | Omeprazole |
|
H<sup>+</sup>,K<sup>+</sup>-ATPase inhibitor (IC<sub>50</sub> = 5.8 <span class='symbol'>μ</span>M) that displays antisecretory and antiulcer activity. Inhibits gastric acid secretion (IC<sub>50</sub> = 0.16 <span class='symbol'>μ</span>M for histamine-induced acid formation) and reduces gastric lesion formation induced by a variety of ulcerative stimuli. Antibacteral against <em>Helicobacter pylori</em> <em>in vitro</em>. Also inhibits CYP2C19, CYP2C9 and CYP3A (K<sub>i</sub> values are 3.1, 40.1 and 84.4 <span class='symbol'>μ</span>M respectively) and blocks swelling-dependent chloride channels (ICIswell).
|
|
| BCC1255 | OSU-03012 (AR-12) |
|
PDPK1 (PDK1) inhibitor; inhibits Akt signaling. Induces apoptosis of PC-3 and medulloblastoma cells, and inhibits growth of a number of tumor cell lines. Sensitizes radiotherapy-induced cell death and enhances cytotoxic effects of chemotherapeutic agents in vitro. Attenuates tumor growth of medulloblastoma xenografts in mice.
|
|
| BCC1256 | Leflunomide |
|
Inhibitor of dihydroorotate dehydrogenase (IC<sub>50</sub> = 2.5 <span class='symbol'>μ</span>M). Inhibits <em>de novo</em> pyrimidine synthesis in human T cells <em>in vitro</em>; also inhibits lymphocyte proliferation. Exhibits efficacy in several animal models of autoimmune disease, arthritis and graft rejection. Active metabolite, teriflunomide(A77 1726), also available.
|
|
| BCC1257 | Doxazosin Mesylate |
|
Selective <span class='symbol'>α</span><sub>1</sub>-adrenoceptor antagonist (pK<sub>i</sub> values are 9.0, 8.5 and 8.4 for human <span class='symbol'>α</span><sub>1B</sub>, <span class='symbol'>α</span><sub>1A</sub> and <span class='symbol'>α</span><sub>1D</sub> receptors respectively). Displays antihypertensive activity.
|
|
| BCC1259 | Flumazenil |
|
Benzodiazepine antagonist, non-selective for <span class='symbol'>α</span>1, <span class='symbol'>α</span>2, <span class='symbol'>α</span>3 or <span class='symbol'>α</span>5-containing GABA<sub>A</sub> receptors. Centrally active upon systemic administration <em>in vivo</em>.
|
|
| BCC1262 | Loratadine |
|
Peripheral histamine H1 receptor antagonist (Ki = 35 nM); devoid of central effects. Orally active antiallergic agent.
|
|